LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
[1] Georgina P Sava, et al. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
[1] Georgina P Sava, et al. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.